/

OVID

Ovid Therapeutics Inc.Pre-market

2.19−0.22 −9.13%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

2.41

Prev close

2.41

Day range

2.182.42

52-week range

1.183.11

Volume

1.64M1.04×

Mkt cap

427.70M

P/E ttm

—

Fwd P/E

-5.84

EPS ttm

-0.2200

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−29.47%

Price Chart

Yahoo Finance · delayed

OVIDOct 13, 2026O 2.41H 2.41L 2.18C 2.19−0.22 (−9.13%)Vol 1.64M

SMA 502.64
SMA 2002.32

1Y change +38.61% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

OVID Ovid Therapeutics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.59%
1 month: −18.59%
3 months: −10.98%
6 months: −26.01%
Year to date: +34.36%
1 year: +38.61%

Valuation & ownership

Market cap: 427.70M
Enterprise value: 323.20M
P/E (ttm): —
Forward P/E: -5.84
PEG ratio: —
Price / book: 1.93
Price / sales (ttm): 270.18
EV / EBITDA: -5.58
EPS (ttm): -0.2200
EPS (forward): -0.3750
Beta (5y monthly): 0.23
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 195.30M
Float: 163.39M
Short % of float: 11.11%
Short ratio (days): 11.15
Held by insiders: 6.72%
Held by institutions: 80.42%
Avg volume (3m): 1.57M
50-day average: 2.65
200-day average: 2.32
52-week change: +38.61%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 32.9
vs 50-day SMA: −17.14%
vs 200-day SMA: −5.70%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.39%
Realised vol (20d, ann.): 53.4%
From 52-week high: −29.47%
From 52-week low: +85.59%

ANR

Analyst Consensus

10 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

6.02

+175.07% implied

Low 4.00Median 5.12High 9.00

Recommendation trend

Now12 / 0 / 0
1m ago10 / 0 / 0
2m ago

DES

About Ovid Therapeutics Inc.

Yahoo Finance profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 23
Headquarters: New York, NY, United States
Website: ovidrx.com
Officers: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. Co-Founder & Executive Chairman
Ms. Margaret Alexander CEO, President & Director
Mr. Jeffrey A. Rona Advisor
Mr. Charles Ross Carter M.B.A., M.S.

SEAS

Seasonality · OVID

2017–2026 · monthly returns

Strongest month Nov +22.96%Weakest month Dec −16.22%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.3	4.5	36.2	24.8	-1.4	-1.5	-17.5	20.3	-6.7	-12.0			+34.4%
2025	-29.0	-20.1	-41.1	4.8	-16.8	21.3	51.5	156.0	1.6	6.9	28.1	-8.4	+74.5%
2024	20.2	-12.1	-10.3	0.0	0.3	-74.9	35.2	8.7	4.4	-4.2	0.9	-18.1	−71.0%
2023	34.4	-1.2	4.5	38.8	-1.1	-7.3	9.5	-6.3	14.1	-7.6	-16.2	8.2	+73.1%
2022	-14.0	22.8	-7.4	-12.4	-38.5	27.2	-4.7	-2.0	-8.5	-11.4	8.6	5.1	−42.1%
2021	21.6	5.0	36.3	-8.7	13.1	-5.8	-4.6	-5.4	-4.8	1.2	-1.5	-4.2	+39.0%
2020	-13.3	-8.9	-9.1	22.1	47.0	37.8	-12.5	-11.0	0.0	-11.0	33.9	-66.2	−44.3%
2019	16.9	-27.2	-14.1	15.3	-21.6	15.6	10.3	-13.2	83.1	-28.7	84.4	-2.6	+71.5%
2018	-13.9	-22.5	7.3	34.1	-16.8	-1.1	27.9	-33.2	-15.0	-9.5	-21.4	-40.0	−75.5%
2017						-17.7	-21.9	15.0	-9.0	-24.4	90.0	-19.8	−22.6%

INSD

Insider Activity · OVID

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 5, 2026	Carter Charles RossChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	50K	—
Apr 6, 2026	Papadopoulos Stelios BDirector	Stock Award(Grant) at price 2.56 per share.	17.6K	$45.00K
Apr 6, 2026	Friedman BartDirector	Stock Award(Grant) at price 2.56 per share.	8.8K	$22.50K
Apr 6, 2026	Fitzgerald Kevin JosephDirector	Stock Award(Grant) at price 2.56 per share.	17.6K	$45.00K
Mar 22, 2026	Levin Jeremy MOfficer and Director	Conversion of Exercise of derivative security at price 1.40 per share.	47.3K	$66.27K
Feb 25, 2026	Rona Jeffrey AOfficer	Stock Award(Grant) at price 0.00 per share.	68.1K	—
Feb 22, 2026	Rona Jeffrey AOfficer	Sale at price 1.45 per share.	8.5K	$12.38K
Feb 22, 2026	Alexander Margaret A.Chief Executive Officer	Sale at price 1.45 per share.	11.7K	$16.90K
Dec 14, 2025	Levin Jeremy MChief Executive Officer	—	71K	—
Dec 7, 2025	Takeda Pharmaceutical Co., Ltd.Beneficial Owner of more than 10% of a Class of Security	—	1.25M	—
Feb 25, 2025	Rona Jeffrey AChief Financial Officer	Sale at price 0.56 per share.	3.9K	$2.19K
Feb 25, 2025	Alexander Margaret A.President	Sale at price 0.56 per share.	5.3K	$2.96K
Feb 19, 2025	Rona Jeffrey AChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	43.8K	—
Feb 19, 2025	Alexander Margaret A.President	Stock Award(Grant) at price 0.00 per share.	43.8K	—
Jan 26, 2025	Alexander Margaret A.President	Purchase at price 0.73 per share.	6.8K	$4.97K

13F

Investors Holding OVID

latest 13F filings of 29 followed managers

Investors holding OVID
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$283.8K	0.00%	105.50K	−90%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

OVID

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

OVID

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ovid Therapeutics Inc.

Seasonality · OVID

Insider Activity · OVID

Congress Trades · OVID

Investors Holding OVID

Investors Holding OVID

Congress Trades · OVID

Insider Activity · OVID

Seasonality · OVID

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ovid Therapeutics Inc.

Financial Snapshot

Earnings & Dividends

News